Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.02.2024 | Case report

Gefitinib/Immune-globulin/Osimertinib

Lack of efficacy, keratitis and toxic epidermolysis necrotizing disease

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Xu Y, et al. Osimertinib-induced Keratitis and Secondary Toxic Epidermal Necrotic Drug Eruption- A Case Report and Literature Review. [Review] Current Drug Safety 19 : 309-312, No. 2, Jan 2024. Available from: URL: https://dx.doi.org/10.2174/1574886318666230529123200 Xu Y, et al. Osimertinib-induced Keratitis and Secondary Toxic Epidermal Necrotic Drug Eruption- A Case Report and Literature Review. [Review] Current Drug Safety 19 : 309-312, No. 2, Jan 2024. Available from: URL: https://dx.doi.org/10.2174/1574886318666230529123200
Metadaten
Titel
Gefitinib/Immune-globulin/Osimertinib
Lack of efficacy, keratitis and toxic epidermolysis necrotizing disease
Publikationsdatum
01.02.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-53000-4

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Elasomeran

Case report

Multiple drugs

Case report

Tamoxifen